検索結果

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

adquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that the orphan drug designation to the in-house developed compound having the development code SJP-0008 ...

Business Activities | About Senju | SENJU Pharmaceutical

Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph...

tical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osak...

Quality Policies | About Senju | SENJU Pharmaceutical

We will set the following "Quality Policies" and continue to be a "Good Company" by encouraging cooperation among all employees and providing high-quality products for "realiz...